Dyadic International Inc. Common Stock (DYAI)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Dyadic International is a biotechnology platform company with proprietary Dapibus and C1 protein production platforms. It has only 5 employees. In fiscal year 2025, the year ended 2025-12-31, revenue was $3.1M and net income was -$7.4M. In fiscal year 2024, revenue was $3.5M and net income was -$5.8M. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $961,138 and net loss was $2.1M, versus revenue of $966,630 and net loss of $1.8M in fiscal Q2 2025. So the top line is not growing enough to cover costs. Trailing free cash flow is -$7.4M, and FairStock's FCF yield is -47.3% on a $15.7M market cap. FairStock's calculations show a strained picture: D/E 4.11, Altman Z -20.39, Piotroski 2/9, ROE -2826.92%, ROCE -62.99%. At the $0.43 close on 2026-10-13, P/B is 24.00, so the market is paying a large multiple of book for a loss-making business. FairStock score is 13/100 and no Peter Lynch category because it lost money in each of the last four years. I see no durable moat or consistent earnings power. The platform could have option value, but as a Graham-style investment, I need a margin of safety in earnings or assets, and neither is present. I would wait for evidence of commercial traction and a path to positive cash flow.

In plain English: Dyadic International makes and sells protein and enzyme production technology for food, nutrition, and industrial uses. It is very small, losing money, and its revenue has shrunk, so the business looks weak. At 43 cents a share, the price looks expensive compared with its profits and assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer